Physiological SCFAs may worsen alpha-synuclein pathology through FFAR2/GPR43-NL…

Mechanistic description

A key liability hypothesis is that low-range SCFA signaling can be receptor-biased toward inflammasome activation in susceptible contexts, increasing IL-1beta and neuroinflammation rather than aggregate disposal. This is not a development thesis, but it is a high-priority safety gate because it could explain why physiologic SCFA elevation is ineffective or harmful in some synucleinopathy settings.

Mechanism / pathway

FFAR2/NLRP3/IL1B
→
neurodegeneration

Evidence for (7)

Gut microbial SCFAs promoted motor deficits, microglial activation, and alpha-syn pathology in a synucleinopathy mouse model.

PMID:27912057
A newer study linked SCFA-driven pathology to GPR43-NLRP3 signaling, directly supporting an inflammatory liability mechanism.

PMID:39904963
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.

PMID:32048886 2021 Autophagy
Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease.

PMID:34691027 2021 Front Immunol
ASC specks exacerbate α‑synuclein pathology via amplifying NLRP3 inflammasome activities.

PMID:36740674 2023 J Neuroinflammation
Biomarker of Neuroinflammation in Parkinson's Disease.

PMID:35456966 2022 Int J Mol Sci
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice.

PMID:30381407 2018 Sci Transl Med

Evidence against (2)

These models are context-dependent and do not establish that confirmed physiologic human-equivalent micromolar exposure will impair microglial aggregate clearance in vivo.

PMID:39904963
Worsened phenotype could arise from peripheral immune or gut effects rather than direct failure of microglial alpha-syn disposal.

PMID:27912057

Evidence matrix

7 supporting 2 contradicting

78% supporting

Supporting

Gut microbial SCFAs promoted motor deficits, microglial activation, and alpha-syn pathology in a synucleinopathy mouse model. PMID:27912057
A newer study linked SCFA-driven pathology to GPR43-NLRP3 signaling, directly supporting an inflammatory liability mechanism. PMID:39904963
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles. PMID:32048886 · 2021 · Autophagy
Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease. PMID:34691027 · 2021 · Front Immunol
ASC specks exacerbate α‑synuclein pathology via amplifying NLRP3 inflammasome activities. PMID:36740674 · 2023 · J Neuroinflammation
Biomarker of Neuroinflammation in Parkinson's Disease. PMID:35456966 · 2022 · Int J Mol Sci
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. PMID:30381407 · 2018 · Sci Transl Med

Contradicting

These models are context-dependent and do not establish that confirmed physiologic human-equivalent micromolar exposure will impair microglial aggregate clearance in vivo. PMID:39904963
Worsened phenotype could arise from peripheral immune or gut effects rather than direct failure of microglial alpha-syn disposal. PMID:27912057

Cite this hypothesis

Citation

etl-backfill (2026). Physiological SCFAs may worsen alpha-synuclein pathology through FFAR2/GPR43-NL…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-9e877c49ba

BibTeX

@misc{scidex_hypothesis_h9e877c4,
  title        = {Physiological SCFAs may worsen alpha-synuclein pathology through FFAR2/GPR43-NL…},
  author       = {etl-backfill},
  year         = {2026},
  howpublished = {SciDEX hypothesis},
  url          = {https://prism.scidex.ai/hypotheses/h-9e877c49ba},
  note         = {SciDEX artifact hypothesis:h-9e877c49ba}
}